FALSE000181809300018180932025-03-122025-03-120001818093us-gaap:CommonStockMember2025-03-122025-03-12

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2025
 
The Beauty Health Company
(Exact name of registrant as specified in its charter)  
 
Delaware 001-39565 85-1908962
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2165 Spring Street
Long Beach, CA
(Address of principal executive offices)

90806
(Zip Code)
(800) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001 per share SKIN 
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  
 


Item 2.02. Results of Operations and Financial Condition.

On March 12, 2025, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The Company is making reference to non-GAAP financial information in both the press release and the conference call. A reconciliation of GAAP to non-GAAP results is provided in the attached Exhibit 99.1 press release.

The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, and on the Company’s investor relations website (https://investors.beautyhealth.com/) as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: March 12, 2025
The Beauty Health Company
By:/s/ Michael Monahan
Name:Michael Monahan
Title:Chief Financial Officer

Exhibit 99.1
BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results
Delivers fourth quarter and full year net sales of $83.5 million and $334.3 million

Long Beach, Calif., March 12, 2025 – The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship brand Hydrafacial, today announced financial results for the fourth quarter ended December 31, 2024 (“Q4 2024”).

“In Q4 2024, we continued to strengthen our financial position, exceeding the high end of our guidance for both net sales and adjusted EBITDA,” said CEO Marla Beck. “We increased consumable sales, expanded our gross margins and continued to reduce our operating expenses, delivering $9 million of adjusted EBITDA in the quarter. We now have over 34,000 global delivery systems serving our large provider base.”

“In 2025, we are focused on deepening partnerships, accelerating science-backed innovations, including new product offerings, and enhancing our commercial execution. Despite near-term global macroeconomic uncertainty and industry headwinds, Hydrafacial remains a leading global brand, and we are confident in our ability to execute on our strategy and drive long-term shareholder value.”

Key Operational and Business Metrics
Three Months Ended December 31,Year Ended December 31,
Unaudited ($ in millions) (1)
2024202320242023
Delivery Systems net sales$26.8 $44.6 $125.4 $206.6 
Consumables net sales56.7 52.2 208.9 191.4 
Total net sales
$83.5 $96.8 $334.3 $398.0 
Gross profit$52.3 $45.7 $182.3 $155.1 
Gross margin62.7 %47.2 %54.5 %39.0 %
Adjusted gross profit(2)
$56.0 $52.8 $207.2 $249.8 
Adjusted gross margin(2)
67.1 %54.6 %62.0 %62.8 %
Net loss$(10.3)$(9.4)$(29.1)$(100.1)
Adjusted EBITDA(2)
$9.0 $3.4 $12.3 $24.3 
Adjusted EBITDA margin(2)
10.8 %3.5 %3.7 %6.1 %

Three Months Ended December 31,Year Ended December 31,
Unaudited
2024202320242023
Total delivery systems sold
1,087 1,551 4,907 8,287 
Active install base(3)
34,735 31,446 34,735 31,446 
__________________________
(1) Amounts may not sum due to rounding.
(2) See "Non-GAAP Financial Measures" below.
(3) Estimated number of delivery systems owned by providers that have purchased consumables in the trailing twelve-month period.

BeautyHealth completed the year with an estimated active install base of 34,735 units, as compared to 31,446 in the prior year, resulting in growth in consumable net sales. The decrease in overall revenue resulted from fewer units placed year over year, impacted by a challenging macroeconomic environment and the prior year international launch of the Syndeo Delivery System ("Syndeo"). The Company continues to evaluate its strategic footprint, exiting its third-party manufacturing arrangement in 2024, and is expected to convert its China market from a direct sales to distributor model in 2025.

1

Fourth Quarter Financial Highlights
•Net sales were $83.5 million for the fourth quarter of 2024, a decrease of (13.8)%, compared to the prior year period ("Q4 2023"), due to lower delivery systems net sales.
•Gross margin was 62.7% in Q4 2024 compared to 47.2% in Q4 2023. Adjusted gross margin was 67.1% in Q4 2024 compared to 54.6% in Q4 2023. The improvement in gross margin and adjusted gross margin was primarily due lower inventory related charges and favorable mix shift towards consumable net sales, partially offset by lower average selling price of equipment net sales.
•Net loss was relatively flat at $(10.3) million in Q4 2024 compared to $(9.4) million in Q4 2023.
•Adjusted EBITDA was $9.0 million in Q4 2024 compared to $3.4 million in Q4 2023. The improvement in adjusted EBITDA was primarily due to lower operational spend and higher gross margin, partially offset by lower net sales.
•The Company placed 1,087 delivery systems during the quarter compared to 1,551 in the prior year period, reflecting a challenging macroeconomic environment in addition to the prior year international launch of Syndeo.

Full Year Financial Highlights
•Net sales were $334.3 million for 2024, a decrease of (16.0)%, compared to the prior year due to lower delivery systems net sales.
•Gross margin was 54.5% in 2024 compared to 39.0% in 2023. The improvement in gross margin was primarily due to the absence of charges and inventory write-downs associated with the Syndeo Program of $65.2 million in 2023 and favorable mix shift towards consumable net sales, partially offset by higher inventory related charges and $8 million of manufacturing optimization related costs incurred in 2024.
•Adjusted gross margin was relatively flat at 62.0% in 2024 compared to 62.8% in 2023.
•Net loss was $(29.1) million in 2024 compared to net loss of $(100.1) million in 2023. The change compared to the prior year was primarily due to costs associated with the Syndeo Program in 2023.
•Adjusted EBITDA was $12.3 million in 2024 compared to $24.3 million in 2023. The decline in adjusted EBITDA was primarily due to lower net sales, partially offset by lower operational spend.
•The Company placed 4,907 delivery systems in 2024 compared to 8,287 in the prior year, reflecting a challenging macroeconomic environment in addition to the prior year international launch of Syndeo.

Balance Sheet and Cash Flow Highlights
•Cash, cash equivalents, and restricted cash were approximately $370.1 million as of December 31, 2024 compared to approximately $523.0 million as of December 31, 2023. The change was primarily due to the repurchase of convertible senior notes during the first half of 2024.
•The Company had approximately 7 million private placement warrants and approximately 124.9 million shares of Class A common stock outstanding as of December 31, 2024.

2025 Financial Guidance
First Quarter 2025
Net sales$61 – $66 million
Adjusted EBITDA(1)
($6) – ($4) million
Fiscal Year 2025
Net sales$270 – $300 million
Adjusted EBITDA(1)
$10 – $25 million
__________________________
(1) See "Non-GAAP Financial Measures" below.

2

2025 financial guidance reflects the following assumptions:
•Net sales guidance reflects continued downward pressure on delivery systems net sales.
•Assumes no material deterioration in current general market conditions or other unforeseen circumstances beyond the Company's control, such as foreign currency exchange rates, tariffs, and trade restrictions.
•Excludes any unannounced acquisitions, dispositions or financings.

Regional Operational and Business Metrics
Three Months Ended December 31,Year Ended December 31,
Unaudited ($ in millions) (1)
2024202320242023
Delivery Systems net sales
Americas$16.8 $21.8 $70.9 $95.0 
Asia-Pacific (“APAC”)2.8 13.0 21.7 59.4 
Europe, the Middle East and Africa (“EMEA”)7.2 9.8 32.8 52.2 
Total Delivery Systems net sales$26.8 $44.6 $125.4 $206.6 
Consumables net sales
Americas$40.2 $37.5 $146.0 $132.7 
APAC
6.5 5.7 24.0 22.8 
EMEA10.0 9.0 38.9 35.9 
Total Consumables net sales$56.7 $52.2 $208.9 $191.4 
Net sales
Americas$57.1 $59.4 $217.0 $227.7 
APAC
9.2 18.7 45.7 82.2 
EMEA17.2 18.8 71.6 88.1 
Total net sales$83.5 $96.8 $334.3 $398.0 
Delivery Systems sold
Americas649 758 2,695 3,603 
APAC
140 450 911 2,392 
EMEA298 343 1,301 2,292 
Total Delivery Systems sold1,087 1,551 4,907 8,287 
__________________________
(1) Amounts may not sum due to rounding.

Conference Call
BeautyHealth will host a conference call on Wednesday, March 12, 2025, at 4:30 p.m. ET to review its fourth quarter and full year 2024 financial results. The call may be accessed via live webcast through the Events & Presentations page on our Investor Relations website at https://investors.beautyhealth.com. A replay of the conference call will be available approximately three hours after the conclusion of the call and can be accessed online at https://investors.beautyhealth.com.

3

Non-GAAP Financial Measures
In addition to results determined in accordance with accounting principles generally accepted in the United States of America ("GAAP"), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes.

Management believes that these non-GAAP financial measures, when reviewed collectively with the Company’s GAAP financial information, provide useful supplemental information to investors in assessing the Company's operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to unusual items.

Adjusted gross profit is gross profit excluding the effects of depreciation expense, amortization expense, share-based compensation expense and other items such as manufacturing optimization costs; write-off of discontinued, excess and obsolete product; Syndeo Program; Syndeo product optimization logistics & service costs; and Go-to-Market restructuring. Adjusted gross margin represents adjusted gross profit as a percentage of net sales.

Adjusted EBITDA is calculated as net loss excluding the effects of (benefit) expense for income taxes; depreciation expense; amortization expense; share-based compensation expense; interest expense; interest income; other (income) expense, net; change in fair value of warrant liabilities; foreign currency loss (gain), net; manufacturing optimization costs; write-off of discontinued, excess and obsolete product; Syndeo Program; Syndeo product optimization logistics & service costs; Go-to-Market restructuring; litigation related costs; transaction related costs; and severance, restructuring and other. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of net sales.

The Company does not provide a reconciliation of its fiscal 2025 adjusted EBITDA guidance to net loss, the most directly comparable forward looking GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash share-based compensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2025 adjusted EBITDA guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See “Forward-Looking Statements” for additional information.


4

The Beauty Health Company
Consolidated Statements of Comprehensive Loss (1)
($ in millions, except share and per share amounts)
(Unaudited)

Three Months Ended December 31,Year Ended December 31,
2024202320242023
Net sales$83.5 $96.8 $334.3 $398.0 
Cost of sales31.1 51.1 152.0 242.9 
Gross profit52.3 45.7 182.3 155.1 
Operating expenses:
Selling and marketing26.5 32.0 118.3 144.5 
Research and development1.2 3.0 6.3 10.1 
General and administrative31.8 29.0 125.5 131.4 
Total operating expenses59.5 64.0 250.1 286.0 
Loss from operations(7.2)(18.4)(67.8)(130.9)
Interest expense2.5 3.4 10.4 13.6 
Interest income(2.2)(6.4)(16.6)(23.2)
Other (income) expense, net(0.1)0.1 (33.6)(5.2)
Change in fair value of warrant liabilities(0.1)(3.6)(3.1)(11.9)
Foreign currency transaction loss (gain), net4.5 (3.1)4.6 (2.4)
Loss before provision for income taxes(11.7)(8.8)(29.6)(101.9)
Income tax (benefit) expense(1.4)0.6 (0.5)(1.8)
Net loss(10.3)(9.4)(29.1)(100.1)
Comprehensive loss, net of tax:
Foreign currency translation adjustments(3.2)2.1 (3.9)1.5 
Comprehensive loss$(13.6)$(7.3)$(33.0)$(98.6)
Net loss per share
Basic$(0.08)$(0.07)$(0.23)$(0.76)
Diluted$(0.08)$(0.07)$(0.36)$(0.76)
Weighted average common shares outstanding
Basic124,401,969 128,716,355 123,827,372 131,680,605 
Diluted124,401,969 128,716,355 142,492,575 131,680,605 
__________________________
(1)Amounts may not sum due to rounding.


5

The Beauty Health Company
Consolidated Balance Sheets (1)
($ in millions)
(Unaudited)
December 31, 2024December 31, 2023
ASSETS
Current assets:
Cash, cash equivalents, and restricted cash$370.1$523.0
Accounts receivable, net27.654.7
Inventories 69.191.3
Income tax receivable 0.80.3
Prepaid expenses and other current assets9.528.9
Total current assets477.1698.3
Property and equipment, net6.014.2
Right-of-use assets, net13.612.1
Intangible assets, net 47.562.1
Goodwill123.5125.8
Deferred income tax assets, net3.90.5
Other assets 14.116.0
TOTAL ASSETS$685.7$929.1
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$21.9$44.8
Accrued payroll-related expenses17.622.0
Lease liabilities, current5.14.6
Income tax payable3.42.8
Syndeo Program reserves
—21.0
Other accrued expenses20.019.8
Total current liabilities 68.2115.0
Lease liabilities, non-current10.89.3
Deferred income tax liabilities, net 0.40.7
Warrant liabilities 0.53.6
Convertible senior notes, net552.2738.4
Other long-term liabilities1.82.8
TOTAL LIABILITIES$633.9$869.7
Stockholders’ equity:
Class A Common Stock
$— $— 
Additional paid-in capital 566.7 541.3 
Accumulated other comprehensive loss(7.0)(3.0)
Accumulated deficit(508.0)(478.9)
Total stockholders’ equity$51.8 $59.4 
 LIABILITIES AND STOCKHOLDERS’ EQUITY$685.7 $929.1 
__________________________
(1)Amounts may not sum due to rounding.



6

The Beauty Health Company
Consolidated Statement of Cash Flows (1)
($ in millions)
(Unaudited)


Year Ended December 31,
20242023
Cash, cash equivalents, and restricted cash at beginning of period$523.0$568.2
Operating activities:
Net loss(29.1)(100.1)
Non-cash adjustments:72.6 98.5 
Change in operating assets and liabilities:
Accounts receivable20.8 16.5 
Inventories(10.5)(22.6)
Prepaid expenses, other current assets, and income tax receivable15.5 (7.0)
Accounts payable, accrued expenses, and income tax payable(43.8)44.0 
Other, net(9.4)(7.6)
Net cash provided by operating activities16.1 21.8 
Net cash used for investing activities(6.8)(31.5)
Net cash used for financing activities(158.3)(37.4)
Net change in cash, cash equivalents, and restricted cash(149.0)(47.2)
Effect of foreign currency translation(4.0)2.0 
Cash, cash equivalents, and restricted cash at end of period$370.1 $523.0 
__________________________
(1)Amounts may not sum due to rounding.

The following table reconciles gross profit to adjusted gross profit for the periods presented:
Three Months Ended December 31,Year Ended December 31,
Unaudited ($ in millions) (1)
2024202320242023
Net sales$83.5 $96.8 $334.3 $398.0 
Gross profit$52.3 $45.7 $182.3 $155.1 
Gross margin62.7 %47.2 %54.5 %39.0 %
Adjusted to exclude the following:
Depreciation expense0.4 0.5 2.3 2.4 
Amortization expense2.5 4.2 12.3 13.9 
Share-based compensation expense0.1 0.3 0.1 1.5 
Manufacturing optimization costs— — 7.6 — 
Write-off of discontinued, excess and obsolete product— — 2.0 10.4 
Syndeo Program— 2.1 — 65.2 
Syndeo product optimization logistics & service costs— — — 1.4 
Go-to-Market restructuring0.6 — 0.6 — 
Adjusted gross profit$56.0 $52.8 $207.2 $249.8 
Adjusted gross margin67.1 %54.6 %62.0 %62.8 %
__________________________
(1)Amounts may not sum due to rounding.

7

The following table reconciles net loss to adjusted EBITDA for the periods presented:

Three Months Ended December 31,Year Ended December 31,
Unaudited ($ in millions) (1)
2024202320242023
Net sales$83.5 $96.8 $334.3 $398.0 
Net loss$(10.3)$(9.4)$(29.1)$(100.1)
Adjusted to exclude the following:
(Benefit) expense for income taxes(1.4)0.6 (0.5)(1.8)
Depreciation expense1.5 4.3 9.9 11.3 
Amortization expense5.1 5.6 23.7 23.3 
Share-based compensation expense5.9 2.3 26.7 22.5 
Interest expense2.5 3.4 10.4 13.6 
Interest income(2.2)(6.4)(16.6)(23.2)
Other (income) expense, net(0.1)0.1 (33.6)(5.2)
Change in fair value of warrant liabilities(0.1)(3.6)(3.1)(11.9)
Foreign currency loss (gain), net4.5 (3.1)4.6 (2.4)
Manufacturing optimization costs— — 7.6 — 
Write-off of discontinued, excess and obsolete product— — 2.0 10.4 
Syndeo Program— 2.1 — 65.2 
Syndeo product optimization logistics & service costs— — — 1.4 
Go-to-Market restructuring0.6 — 0.6 — 
Litigation related costs2.6 — 6.3 1.5 
Transaction related costs— — — 0.8 
Severance, restructuring and other0.6 7.4 3.1 18.7 
Adjusted EBITDA$9.0 $3.4 $12.3 $24.3 
Adjusted EBITDA margin10.8 %3.5 %3.7 %6.1 %
__________________________
(1)Amounts may not sum due to rounding.


8

About The Beauty Health Company
The Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in nanoneedling and microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/, and learn more at beautyhealth.com or LinkedIn.

Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding The Beauty Health Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside The Beauty Health Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Important factors that may affect actual results or outcomes include, among others: The Beauty Health Company’s ability to manage growth; The Beauty Health Company’s ability to execute its business plan; potential litigation involving The Beauty Health Company; changes in applicable laws or regulations; the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent filings with the SEC. There may be additional risks that the Company does not presently know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The Beauty Health Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts
Investors: IR@beautyhealth.com
Press: Press@beautyhealth.com
9
v3.25.0.1
Cover
Mar. 12, 2025
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Mar. 12, 2025
Entity Registrant Name The Beauty Health Company
Entity Incorporation, State or Country Code DE
Entity File Number 001-39565
Entity Tax Identification Number 85-1908962
Entity Address, Address Line One 2165 Spring Street
Entity Address, City or Town Long Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90806
City Area Code 800
Local Phone Number 603-4996
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001818093
Class A Common Stock, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol SKIN
Security Exchange Name NASDAQ
Beauth Health (NASDAQ:SKIN)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Beauth Health Charts.
Beauth Health (NASDAQ:SKIN)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Beauth Health Charts.